AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
160.22
+3.66 (+2.34%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close156.56
Open157.78
Bid154.59 x 2200
Ask162.00 x 800
Day's Range156.32 - 160.66
52 Week Range125.84 - 197.00
Volume2,783,098
Avg. Volume2,687,427
Market Cap54.04B
Beta (3Y Monthly)1.36
PE Ratio (TTM)24.40
EPS (TTM)6.57
Earnings DateJan 29, 2019
Forward Dividend & Yield2.88 (1.84%)
Ex-Dividend Date2018-11-09
1y Target Est206.29
Trade prices are not sourced from all markets
  • Cramer's Exec Cut: The biggest names in health—and Apple—...
    CNBC Videos10 days ago

    Cramer's Exec Cut: The biggest names in health—and Apple—...

    Jim Cramer gets a fresh perspective on health-care innovation with Apple, Dexcom, Canopy Growth and more.

  • GlobeNewswire4 hours ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) & Lead Plaintiff Deadline: February 19, 2019

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allergan plc ("Allergan" or the "Company") (AGN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Allergan shares between May 9, 2017, and December 19, 2018, both dates inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. Specifically, the complaint alleges that Allergan concealed from investors the fact that the Company's CE Mark for its textured breast implants and tissue expanders was expiring in Europe.

  • Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?
    Motley Foolyesterday

    Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?

    The answer: It's complicated.

  • Business Wire3 days ago

    ALLERGAN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Allergan plc. - AGN

    Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc. (AGN), if they purchased the Company’s shares between February 24, 2017, and December 19, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

  • GlobeNewswire3 days ago

    SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allergan plc. of Class Action Lawsuit and Upcoming Deadline – AGN

    NEW YORK, Jan. 18, 2019 -- Pomerantz LLP announces that a class action lawsuit has been filed against, Allergan plc. (“Allergan” or the “Company”) (NYSE: AGN) and certain of.

  • ACCESSWIRE4 days ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) & Lead Plaintiff Deadline: February 19, 2019

    NEW YORK, NY / ACCESSWIRE / January 17, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allergan plc ("Allergan" or the "Company") ...

  • ACCESSWIRE5 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allergan plc. of Class Action Lawsuit and Upcoming Deadline– AGN

    NEW YORK, NY / ACCESSWIRE / January 16, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against, Allergan plc. ("Allergan" or the "Company") (AGN) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and indexed under 18-cv-12219, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise, acquired Allergan securities between February 24, 2017, and December 19, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

  • ACCESSWIRE5 days ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) & Lead Plaintiff Deadline - February 19, 2019

    NEW YORK, NY / ACCESSWIRE / January 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allergan plc ("Allergan" or the "Company") ...

  • Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C
    Zacks5 days ago

    Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C

    Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C

  • GlobeNewswire6 days ago

    SHAREHOLDER ALERT: GS XRAY NVDA AGN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, Jan. 15, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.

  • Reuters6 days ago

    Drug companies greet 2019 with U.S. price hikes

    Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world's top-selling medicine, Humira, although the pace of price hikes was slower than last year. The industry has been under pressure by the U.S. President Donald Trump to hold their prices level as his administration works on plans aimed at lowering the costs of medications for consumers in the world's most expensive pharmaceutical market. During a White House meeting with members of his Cabinet, U.S. President Donald Trump on Wednesday said he expected to see a tremendous decrease in drug prices.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Allergan plc.

    # Allergan plc ### NYSE:AGN View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for AGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AGN. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $11.52 billion over the last one-month into ETFs that hold AGN are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • CoolSculpting® and Sonja Morgan Partner To Get Real About Self-Care
    PR Newswire6 days ago

    CoolSculpting® and Sonja Morgan Partner To Get Real About Self-Care

    DUBLIN, Jan. 15, 2019 /PRNewswire/ -- Television personality on Bravo's "The Real Housewives of New York City", philanthropist, fashion lifestyle entrepreneur and mom, Sonja Morgan, is partnering with CoolSculpting, owned by Allergan plc (AGN), as the face of the brand's latest "Let's Get Real About Self-Care" campaign. CoolSculpting, the FDA-cleared non-surgical, clinically proven treatment that eliminates stubborn fat using a patented cooling technology, recognizes that self-care is no longer considered an indulgence, it's essential. In her partnership with CoolSculpting, Morgan will share her self-care tips and her own personal CoolSculpting story.

  • GlobeNewswire7 days ago

    CLASS ACTION UPDATE for NVDA and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Jan. 14, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..

  • GlobeNewswire7 days ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) & Lead Plaintiff Deadline: February 19, 2019

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allergan plc ("Allergan" or the "Company") (AGN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Allergan shares between May 9, 2017, and December 19, 2018, both dates inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose adverse information.

  • GlobeNewswire8 days ago

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of XRAY, NVDA and AGN

    NEW YORK, Jan. 13, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.

  • ACCESSWIRE8 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allergan plc. of Class Action Lawsuit and Upcoming Deadline - AGN

    NEW YORK, NY / ACCESSWIRE / January 13, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against, Allergan plc. ("Allergan" or the "Company") (AGN) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and indexed under 18-cv-12219, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise, acquired Allergan securities between February 24, 2017, and December 19, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

  • GlobeNewswire10 days ago

    ALLERGAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Allergan plc. - AGN

    NEW ORLEANS, Jan. 11, 2019 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 19, 2019 to file lead plaintiff applications.

  • GlobeNewswire10 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allergan plc. of Class Action Lawsuit and Upcoming Deadline– AGN

    Pomerantz LLP announces that a class action lawsuit has been filed against, Allergan plc. (“Allergan” or the “Company”) (AGN) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and indexed under 18-cv-12219, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise, acquired Allergan securities between February 24, 2017, and December 19, 2018, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

  • 7 Pharmaceutical Stocks That Just Raised Prices This Year
    InvestorPlace10 days ago

    7 Pharmaceutical Stocks That Just Raised Prices This Year

    Given the meltdown we've seen across the entire market over the past 16 weeks, many investors may be overlooking company-specific and industry-specific news. One of those pieces of news? That a swath of pharmaceutical stocks are raising their prices in the new year. Pharmaceutical stocks and biotech companies are interesting plays in any market, partly due to their secular business nature. Meaning that, recession or boom, consumers need treatment. Whether it's as large as open heart surgery or small as a Tylenol, we pay for healthcare when we need it. For as secular as the group can be though, it has been under tremendous volatility lately. With that in mind, almost 40 companies started of 2019 with a series of prices hikes. The average raise was roughly 6.3%. So who were these companies and how do we trade their stocks? InvestorPlace - Stock Market News, Stock Advice & Trading Tips * InvestorPlace Roundup: The Hottest Stocks in the Market Today Let's look at a few of those pharmaceutical stocks. ### Allergan (AGN) Allergan (NYSE:AGN) is known for its vast drug and treatment portfolio. However, at the turn of the year, Allergan raised prices on 51 of its products. That's just over half of its portfolio. Of those 51 products, 27 of them saw an increase of 9.5%. The rest were bumped by 4.9%. All that said, Allergan makes the case that it's not a money-hungry cash grab. Rather, the company says it should not see any net gains as a result of the price hikes because it's providing higher rebates and discounts to its distributors. Allergan may say that, but investors sure wish it would help. Analysts expect sales to fall 1.7% this year and another 1.6% next year. On the earnings front, expectations call for a 90-basis-point gain this fiscal year before a 0.7% decline in 2019. Essentially, estimates call for flat earnings growth overall from fiscal 2017 through 2019. That's likely one factor for why the stock has gone from $195 in October to roughly $125 at its December lows. As AGN approaches the $145 to $150 level now, look to see if and where resistance comes into play. There's downtrend resistance at play, as well as the gap-fill up near $145. It would be encouraging to see the $140-ish level hold as support, but that doesn't leave much wiggle room for Allergan. ### Bristol-Myers (BMY) No one is talking about recent dividend payout from Bristol-Myers Squibb (NYSE:BMY), nor are they talking about its recent price increases. The company raised prices on its cancer drugs Opdivo and Yervoy by 1.5%, while lifting prices by 6% on its chemotherapy treatment Sprycel and its autoimmune disease drug Orencia. However, most investors are talking about the company's $74 billion cash and stock acquisition of Celgene (NASDAQ:CELG). BMY was hammered on the news at first, but rebounded by about 4% on Friday once investors were able to digest the news. Management expects the deal to close in the third quarter of 2019. Creating over $2 billion in synergies and boosting growth, BMY management is hoping the acquisition makes its stock more attractive to investors. At just 12 times forward earnings with 8.5% sales growth and 28% earnings growth this year, BMY already looks reasonable. Throw in its 3.5% dividend yield and its even more attractive. * Morgan Stanley: 7 Risky Stocks to Sell Now On the charts, it's clear that dips down to the upper $40s have been viewed as buying opportunities by investors over the last four years. ### Eli Lilly (LLY) Eli Lilly (NYSE:LLY) isn't exempt when it comes to drug price increases, as it raises prices for Jardiance, a treatment for type 2 diabetes, by 6%. Unlike some of its peers, Eli Lilly has been on absolute fire. Shares are up 35% year-over-year and about 60% from its February lows. Despite the rally, LLY still pays out a 2.2% dividend yield and trades at a somewhat reasonable 20.6 times this year's earnings. Despite the big breakout rally in July, LLY has modest growth expectations. Analysts expect 6.8% and 4% sales growth this year and next year, respectively. Further, estimates call for 30.4% earnings growth this year and 6.5% growth in 2019. Fueling the breakout during the summer? A strong second-quarter result and potential IPO for one of its businesses. However, some may feel that LLY stock has rallied too far, too fast and that it's no longer a worthy buy. According to the charts, that may be the case if LLY is unable to push higher and take out its recent highs near $120. If it can break that level, the rally can continue. If not, look to see if uptrend support holds (blue line). Should it fail, LLY could be heading for a retest of its 200-day moving average. ### Pfizer (PFE) Pfizer (NYSE:PFE) delayed various price hikes in 2018, but pushed through its increases at the start of the year. Not many companies have been as open as Allergan about confirming its specific price hikes, but Pfizer may need them to keep pace in 2019. That is to say, PFE was one of the best-performing stocks in the Dow Jones last year. After consolidating between $30 and $36 for most of the last five years, shares finally broke out around the same time Eli Lilly did. In fact, their charts look quite similar too. After a big breakout six months ago, PFE is having trouble pushing higher. Should it fail to get through the 50-day and short-term uptrend support (blue line) gives way, a test of the 200-day moving average could be in the cards. Should it fail as support, a test of $38 is likely in store. Above the 50-day and a rally to $46 is possible. * 10 Stocks You Can Set and Forget (Even In This Market) Investors not worried about the charts will key in on Pfizer's 3.4% dividend yield and its valuation of 14 times this year's earnings. Although remember that 2018's 13.2% earnings growth is expected to slow to just 2.7% in 2019. ### Biogen (BIIB) Biogen (NASDAQ:BIIB) was also on the list of price increases for 2019. The company increased prices on its multiple sclerosis medications Tecfidera by 6%, Plegridy by 2% and Tysabri by 3.5%. Like other biotech stocks, Biogen has been volatile and struggling. Nowhere is this more evident than on the charts. Shares went from $370 in February to $250 in a matter of months, then hit nearly $400 per share in late July. Now near $330, BIIB bulls are near a make-or-break point. The stock has put in a series of lower highs (blue circles) since that big rally in July. Currently, both the 50-day and the 200-day moving averages rest at about $313. Investors who believe BIIB is attractive -- trading at about 12 times forward earnings with expectations to grow sales and earnings 2.5% and 8.5% in 2019, respectively -- will want to see it hold above these two marks. Should it fail, Biogen could quickly head to the bottom of its recent channel, somewhere in the $270 range. On the plus side though, if shares push higher and can close above $340, BIIB may be starting a new uptrend. ### Teva (TEVA) While Warren Buffett's Berkshire Hathaway (NYSE:BRK.B, NYSE:BRK.A) holds a $750 million stake in Teva Pharmaceuticals (NYSE:TEVA), it's far from his largest holding. Big or small, the Oracle has to be disappointed with the stock's recent action, falling from $24 in November to less than $15 at its lows last month. Now up over $17, bulls are hoping Teva stock can continue higher. Will it? Like the others on this list, Teva also raised prices on some of its drugs this year, although the specifics are not well known. So far the name has done well this year, though granted, were just a few sessions into 2019. In any regard, Teva is bumping into the backside of prior downtrend support (blue line). Should this level act as resistance, bulls will want $16.75 to act as support. If not, the recent lows are in play. Over resistance and the $19 to $20 level is on the table. * The 7 Best Stocks in the Entrepreneur Index While the stock trades at less than 7 times this year's earnings, keep in mind that growth has been tough. Sales are forecast to fall 15.8% this year, while analysts expect earnings to contract by 27%. In 2019, the slowdown decelerates, but analysts are still calling for a 4.8% reduction in revenue and a 3% fall in earnings. ### Insys Therapeutics (INSY) Though it is much smaller than most of the names on this list, Insys Therapeutics (NASDAQ:INSY) is joining them in raising prices -- in this case, on its pain-relief medication Subsys. INSY has a market cap of just $350 million. The move is probably necessary, given that sales are forecast to fall about 40.5% this year and another 5% in 2019. It doesn't help that INSY doesn't turn a profit, although its lack of debt is encouraging. Given the selloff we've seen in the stock market since the start of Q4 2018, it's no surprise that investors have cut INSY very little slack. Shares came into Q4 near $10, but are now clinging to the $4.25 level. To say it's been a rough ride would be an understatement. However, INSY is holding up over the $4 level and is right at downtrend resistance. A push higher to $5 would be encouraging, even if this level acts as resistance on its first attempt. But a break below $4 -- especially in the near-term -- would be worrisome and puts the lows back on the table. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 7 Pharmaceutical Stocks That Just Raised Prices This Year appeared first on InvestorPlace.

  • GlobeNewswire10 days ago

    SHAREHOLDER ALERT: YRCW AGN ALKS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, Jan. 11, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.

  • Reuters10 days ago

    Health Canada places restrictions on Allergan's fibroid treatment Esmya

    Canada's health regulator on Friday said it was restricting the use of Allergan Plc's uterine fibroid treatment Esmya after discovering a risk of serious liver injury from the drug. Health Canada said the drug, sold under brand name Fibristal in the country, should not be used by women with liver problems, or those who have had such problems in the past. It also said that more than one treatment course of the drug should be restricted to only those of childbearing age who are unable to undergo surgery to remove the fibroids.

  • Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet
    Zacks10 days ago

    Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet

    Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.

  • Here's Why Editas Medicine Lost 16.6% in December
    Motley Fool11 days ago

    Here's Why Editas Medicine Lost 16.6% in December

    The gene-editing pioneer surprised investors with the departure of its CFO, but there doesn't seem to be any cause for alarm.

  • GlobeNewswire11 days ago

    CLASS ACTION UPDATE for NVDA and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Jan. 10, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..